Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-10-21
1996-05-14
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514318, 546193, 546194, 546257, A61K 3144, C07D21168
Patent
active
055167853
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This application is a 371 of PCT/US92/01451 filed Feb. 27, 1992.
FIELD OF THE INVENTION
This invention relates to anabaseine, DMAB-anabaseine, and anabasine and their use to treat degenerative diseases of the nervous system.
DESCRIPTION OF THE BACKGROUND ART
It has long been customary in classifying diseases of the nervous system to group them as degenerative, thereby indicating they are characterized by a gradually evolving, relentlessly progressive, neuronal death. Science has shown that a considerable portion of disorders that are classed as degenerative are associated with genetic predisposition which results in a pattern of dominant or recessive inheritance. However, others, although they do not differ in a fundamental way from the hereditary disorders, may occur only sporadically as isolated instances within a given family.
As a consequence, since by definition, classification of degenerative diseases cannot be based upon exact knowledge of their cause or pathogenesis, subdivision of these diseases into individual syndromes rests upon descriptive criteria based largely upon pathologic anatomy and consideration of clinical aspects. As a result, this group of diseases presents itself in the form of several clinical syndromes. However, apart from the general differences that allows the distinction of one syndrome from another, there are certain general attributes which typify this entire class of disorders.
The degenerative diseases of the nervous system can typically be divided into disorders characterized by progressive dementia in the absence of other prominent neurologic signs (e.g., Alzheimer's disease, senile dementia, and Pick's disease); syndromes which combine progressive dementia with other prominent neurologic abnormalities (e.g., Huntington's disease, Hallervorden-Spatz, and progressive familial myoclonic epilepsy); syndromes of gradually developing abnormalities of posture and movement (e.g., Parkinson's disease, striatonigral degeneration, torsion dystonia, and Gilles de la Tourette syndrome); syndromes of progressive ataxia (e.g., cerebellar cortical degeneration, olivopontocerebellar atrophy, and Friedgreich's ataxia); and syndromes of muscular weakness and wasting without motor neuron disease (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, and hereditary spastic paraplegia), to name but a few.
Among those diseases listed above, perhaps those most familiar are Alzheimer's and Parkinson's diseases. These diseases are progressive neurological disorders characteristically associated with aging. Alzheimer's disease is characterized by a profound loss of memory and other cognitive functions, while Parkinson's disease is an extrapyramidal movement disorder. Both are invariably fatal. Although there is no effective treatment for Alzheimer's disease, clinical trials are underway with several drugs that increase brain cholinergic transmission. In Parkinson's disease, several treatments are temporarily useful, notably L-DOPA related therapies that replace dopamine in the nigrostriatal pathway. However, in Parkinson's disease the therapeutic efficacy of even the best drugs is temporary at best.
Although the loss of neurons in the late stages of Alzheimer's disease is profound, only a few neuronal pathways appear to be affected in its earliest stages. These include cholinergic projections from the nucleus basalis to the cerebral cortex and from the septum to the hippocampus, noradrenergic projections from the locus cerululus to the cerebral cortex, and several peptidergic neurons that are probably intrinsic to the cerebral cortex. The loss of the aforementioned cholinergic pathways in particular is believed to underlie the early memory loss, since these pathways are known to be important for memory and cognition. This association accounts for the major emphasis in novel cholinergic treatments for Alzheimer's disease, at least in its early stages.
A recent study on Alzheimer's disease demonstrated that loss of cholinergic projections from the nucleus
REFERENCES:
patent: 4155909 (1979-05-01), Sanders
patent: 4183931 (1980-01-01), Wolfe
patent: 4360531 (1982-11-01), McMillan
patent: 4965074 (1990-10-01), Leeson
patent: 5278176 (1994-01-01), Liu
Kem, "A Study of the Occurrence of Anabasine in Paranemertes and Other Nemertines," Toxicon, 9:23-32, 1971.
Waters, "Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease,"Le Journal Canadien Des Sciences Neurologigues, 15:249`256, 1988.
Hu et al., "Chemical Studies on Tobacco Smoke XXIII. Synthesis of Carbon-14 Labelled Myosmine, Nornicotine and N'-Nitrosonornicotine," Journal of Labelled Compounds, 10(1):79-89, 1973.
Leete, "Aberrant Biosynthesis of 5-Fluoroanabasine from 5-Fluoro[5,6-.sup.14 C,.sup.14 C.sub.2 ] nicotinic Acid, Established by Means of Carbon-13 Nuclear Magnetic Resonance," The Journal of Organic Chemistry, 44(2):165-168, 1979.
Leete and Chedekel, "The Aberrant Formation of (-)-N-Methylanabasine From N-Methyl-.increment.-Piperideinium Chloride in Nicotiana Tabacum and N. Glauca," Phytochemistry, 11:2751-2756, 1972.
Seeman et al., "Steric and Conformational Effects in Nicotine Chemistry," J. Org. Chem., 46:3040-3048, 1981.
Meyer et al., "Effects of Nucleus Basalis Lesions on the Muscarinic and Nicotinic Modulation of [.sup.3 H] Acetylcholine Release in the Rat Cerebral Cortex," Journal of Neurochemistry, 49(6):1758-1762, 1987.
Kem, "Structure and Action of Nemertina Toxins," American Zoology, 25:99-111, 1985.
Zoltewicz et al., "Quantitative Determination of the Ring-Chain Hydrolysis Equilibrium Constant for Anabaseine and Related Tobacco Alkaloids," Journal of Organic Chemistry, 64(18):4462-4468, 1989.
Kem et al., "Hoplonemertine Worms--a New Source of Pyridine Neurotoxins," Experientia, 684-686, 1976.
Kem, "Pyridine Alkaloid Distribution in the Hoplonemetines," Hydrobiologia, 156:145-151, 1988.
Kem, "Worm Toxins," Handbook of Natural Toxins, 3:353-378, 1988.
Kem et al., "Isolation and Structure of a Noplonemertine Toxin," Toxicon, 9:15-22, 1971.
Kem, "Biochemistry of Nemertine Toxins," Marine Pharmacognosy, Chapter II, 37:84, 1973.
Windholz, Ed. "Merck Index" p. 6346 (1979).
The Merk Index, p. 657, citation #658 (1976).
Castonguay et al. "Synthesis of C.sup.14 Labeled 4-Methylnitrosalmin-1-(3-pyridyl)-1-Butanone" J. Lab. Radiopharm. 22 23-28 (1985).
Zoltewicz et al. "Hydrolysis of chloinergic Anabaseine . . . " Bio. Org. Chem. 18, 395-412 (1990).
Zoltewicz et al. "Quantitative Determination of the Ring Chain Hydrolysis . . . " J. Org. Chem. 54 4462-68 (1989).
Wiley et al. "Synthesis of 4-methylnicotine-1-(3-pyridyl)-1-Butanone . . . " J.Lab. Radiopharmaceut. 25 707-716 (1988).
Pathak et al. "Synthesis of 4-methynitrasamino-3-pyridyl 1-butanone" Tetrahedron 46 1733-1744 (1990).
Cecil, "Textbook of Medicine" p. 2036, Saunders Company (1983).
Tu, "Handbook of Natural Toxins" Marcel Dekker, pp. 353-360 (1988).
Kem William R.
Meyer Edwin M.
Zoltewicz John A.
Chang Ceila
University of Florida Research Foundation Incorporated
LandOfFree
Use of nicotinic analogs for treatment of degenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of nicotinic analogs for treatment of degenerative diseases , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nicotinic analogs for treatment of degenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1895920